EFX — Equifax Inc.

Analyst consensus is Buy (24 buys, 11 holds, 1 sell) with an average target of $214.36, and Q2 2026 revenue beat expectations with 11% YoY growth. However, the stock is still roughly 30% below its 52-week high, mortgage volumes remain rate-suppressed, and the FICO Mortgage Direct License overhang has not fully cleared. The market is hopeful but not convinced.

Revenue has clearly inflected upward: quarterly revenue went from ~$1.32B in late 2023 to $1.70B in Q2 2026, with YoY growth accelerating from 7.1% in Q3 2025 to 14.3% in Q1 2026 and 10.6% in Q2 2026. EPS has improved from $1.06 in Q1 2025 to $1.42 in Q1 2026 and $1.54 in Q2 2026, although Q2 2026 EPS was only flat versus the prior year. Margins tell a mixed story: Q2 2026 operating margin was 18.5%, down from 20.2% a year earlier, and net margin fell from 12.4% to 10.8%. This is a genuine top-line inflection, but profitability and cash flow have not yet confirmed it — Q2 2026 FCF was $204.8M versus $238.9M a year earlier, even though trailing-twelve-month FCF is up roughly 20% versus the prior four quarters.

By its own history, EFX looks cheap as of 2026-08-27: P/E TTM is 33.2x versus the 5-year average of 46.1x, and P/S is 3.47x versus the 5-year average of 5.52x. Using next-FY consensus EPS of $8.56, the forward P/E is ~22.2x. That discount is deserved in part: PEG is 2.95, D/E is 1.25, the current ratio is only 0.60, and the FICO/mortgage cycle adds real uncertainty. Net: cheap versus its own history, but only reasonably priced once leverage and structural risks are factored in.

At $190.36, the market is paying ~22.2x next-year EPS and roughly 20x trailing FCF per share of ~$9.41. That is a massive de-rating from the 5-year average P/E of 46.1, so the stock is already pricing in meaningful bad news. If consensus 2027 EPS of $8.56 is correct, the current price is roughly fair to modestly undervalued. If the FICO direct-license shift shaves 10–15% off that EPS — to roughly $7.30–$7.70 — fair value drops into the $160–$170 range, which explains why the stock has not already rallied to the $214 analyst target.

As of 2026-08-27, RSI was 59.04, price was 3.66% above the 20-day SMA (~$183.6), 9.25% above the 50-day SMA (~$174.2), and 1.03% above the 200-day SMA (~$188.4). This reflects a short-term uptrend following the post-earnings recovery — not overbought, but no longer at a distressed entry. A pullback toward the $175–$183 zone would offer a better risk/reward for new money, while a confirmed move above $200–$210 would signal the recovery is durable.

• Interest-rate cycle: mortgage and refinancing volumes are the biggest cyclical swing factor; Fed rate cuts would be an immediate tailwind.
• Consumer credit health: a K-shaped normalization with middle-income strain creates uneven demand for credit data and verification services.
• Regulatory and competitive shifts: FICO's Mortgage Direct License Program and VantageScore 4.0 could structurally reduce bureau-centric data monetization.
• AI and cloud transformation: the expanded $150M AI cost-reduction target could expand operating margins even if revenue growth slows.
• Latin America expansion: the Círculo de Crédito acquisition adds international growth but also integration and regulatory risk.

• Q3 2026 earnings (expected late October 2026): updates on Círculo de Crédito integration, AI savings realization, and mortgage inquiry volumes.
• Federal Reserve rate cuts or a meaningful mortgage refinancing pickup would directly re-rate the cyclical earnings power.
• Clearer quantification of the FICO direct-license earnings impact would remove the overhang that has capped the stock.
• Continued compounding in Workforce Solutions (income and employment verifications) as a less cyclical growth engine.

• FICO direct-license disintermediation could reduce mortgage-related credit score revenue; analyst models estimate a 10–15% EPS impact.
• Balance-sheet fragility: D/E of 1.25, current ratio of 0.60, and only $170M cash against $2.63B current liabilities leave limited cushion.
• Mortgage and credit volumes may stay sluggish if rates remain higher for longer, delaying the cyclical recovery.
• Execution risk on the $150M AI cost-saving target and the Círculo de Crédito acquisition could disappoint earnings estimates.
• The cheap historical valuation could persist or get cheaper if fundamental weakness continues — value trap risk is real.

EFX is a high-quality data franchise with real top-line momentum and a clear cost-saving catalyst, but the deterministic score and balance-sheet metrics say the fundamentals are still weak. At $190.36 the stock is not an obvious chase; the better play is to wait for a pullback toward the $175–$183 area or for confirmation of rate cuts and FICO clarity. This is analysis, not personalized investment advice.

Applied a 23.5x forward P/E to next-FY consensus EPS of $8.56 — a large discount to EFX's 5-year average P/E of 46.1x to reflect high leverage, weak current ratio, and FICO/mortgage risk, but a modest premium to the current 22.2x forward multiple to reflect the accelerated revenue trend and AI cost-saving program.